摘要
目的：比较米氮平与氟西汀治疗帕金森氏病伴发抑郁焦虑的疗效及不良反应。方法：67例帕金森氏病伴发抑郁焦虑病人，随机分2组。米氮平组34例，男22例，女12例；年龄45—73岁，平均（66．66±12．37）岁；给予米氮平30mg，po，qd，6W为一个疗程。氟西汀组33例，男23例，女10例；年龄41-72岁，平均（54．96±11．81）岁；给予氟西汀20mg,po,qd，6W为一个疗程。采用汉密顿抑郁量表（HAMD），汉密顿焦虑量表（HAMA），药物副反应量表（TESS）分别评定。结果：对抑郁症状的治疗，米氮平组显效率76，47％，氟西汀组显效率75．76％，疗效差异无显著性（P〉0．05）；对焦虑症状的治疗，米氮平组显效率76．47％，氟西汀组显效率60．61％，疗效差异无显著性（P〉0.05）。药物不良反应发生率2组相当。结论：米氮平与氟西汀对帕金森氏病伴发抑郁焦虑安全有效。
Objective ：To study clinical efficacy and safety of mina, pin and flouxetine in the Parkinson＇s disease （PD） with depression and anxiety. Methods：67 PD with depression and anxiety patients were randomly divided into two groups： mirtazapine group of 34 patients were treated with mirtazapine 30 mg/d, po, qd for six weeks, flouxetine group of 33 patients were treated with flouxetine 20 mg/d, po, qd for six weeks. Results： The marked effective rate of mirtazapine group and flouxetine group were 76.47% and 75.76% （ P 〉 0.05 ） in treating depression symptoms, but the marked effective rate of mirtazapine group and flouxetine group were 76.47% and 60.61% （P 〉 0.05 ） in treating anxiety symptoms. The adverse reactions in mirtazapine group and flouxetine group should no significant difference. Conclusions： mirtazapine shows same effective in treating PD with depression and anxiety compared to flouxetine.
出处
《中国民康医学》
2006年第23期1000-1001,共2页
Medical Journal of Chinese People’s Health
关键词
帕金森氏病
抑郁焦虑
米氮平
氟西汀
Parkinson＇ s disease
Depression and anxiety
Mirtazapine
Flouxetine
